Literature DB >> 23214401

Phosphatidylserine-induced factor Xa dimerization and binding to factor Va are competing processes in solution.

Rinku Majumder1, Tilen Koklic, Alireza R Rezaie, Barry R Lentz.   

Abstract

A soluble, short chain phosphatidylserine, 1,2-dicaproyl-sn-glycero-3-phospho-l-serine (C6PS), binds to discrete sites on FXa, FVa, and prothrombin to alter their conformations, to promote FXa dimerization (K(d) ~ 14 nM), and to enhance both the catalytic activity of FXa and the cofactor activity of FVa. In the presence of calcium, C6PS binds to two sites on FXa, one in the epidermal growth factor-like (EGF) domain and one in the catalytic domain; the latter interaction is sensitive to Na(+) binding and probably represents a protein recognition site. Here we ask whether dimerization of FXa and its binding to FVa in the presence of C6PS are competitive processes. We monitored FXa activity at 5, 20, and 50 nM FXa while titrating with FVa in the presence of 400 μM C6PS and 3 or 5 mM Ca(2+) to show that the apparent K(d) of FVa-FXa interaction increased with an increase in FXa concentration at 5 mM Ca(2+), but the K(d) was only slightly affected at 3 mM Ca(2+). A mixture of 50 nM FXa and 50 nM FVa in the presence of 400 μM C6PS yielded both Xa homodimers and Xa·Va heterodimers, but no FXa dimers bound to FVa. A mutant FXa (R165A) that has reduced prothrombinase activity showed both weakened dimerization (K(d) ~ 147 nM) and weakened FVa binding (apparent K(d) values of 58, 92, and 128 nM for 5, 20, and 50 nM R165A FXa, respectively). Native gel electrophoresis showed that the GLA-EGF(NC) fragment of FXa (lacking the catalytic domain) neither dimerized nor formed a complex with FVa in the presence of 400 μM C6PS and 5 mM Ca(2+). Our results demonstrate that the dimerization site and FVa-binding site are both located in the catalytic domain of FXa and that these sites are linked thermodynamically.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23214401      PMCID: PMC3544317          DOI: 10.1021/bi301239z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  45 in total

1.  Strategy for analysing the co-operativity of intramolecular interactions in peptides and proteins.

Authors:  A Horovitz; A R Fersht
Journal:  J Mol Biol       Date:  1990-08-05       Impact factor: 5.469

2.  Roles of factor Va heavy and light chains in protein and lipid rearrangements associated with the formation of a bovine factor Va-membrane complex.

Authors:  V Koppaka; W F Talbot; X Zhai; B R Lentz
Journal:  Biophys J       Date:  1997-11       Impact factor: 4.033

3.  Extracellular calcium activity in the injured spinal cord.

Authors:  B T Stokes; P Fox; G Hollinden
Journal:  Exp Neurol       Date:  1983-06       Impact factor: 5.330

4.  Sodium binding site of factor Xa: role of sodium in the prothrombinase complex.

Authors:  A R Rezaie; X He
Journal:  Biochemistry       Date:  2000-02-22       Impact factor: 3.162

5.  Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex.

Authors:  S W Kim; T L Ortel; M A Quinn-Allen; L Yoo; L Worfolk; X Zhai; B R Lentz; W H Kane
Journal:  Biochemistry       Date:  1999-08-31       Impact factor: 3.162

6.  Phosphatidylserine binding alters the conformation and specifically enhances the cofactor activity of bovine factor Va.

Authors:  Xin Zhai; Arvind Srivastava; Daryl C Drummond; David Daleke; Barry R Lentz
Journal:  Biochemistry       Date:  2002-04-30       Impact factor: 3.162

7.  Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding.

Authors:  A K Sabharwal; K Padmanabhan; A Tulinsky; A Mathur; J Gorka; S P Bajaj
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

8.  The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex.

Authors:  Rinku Majumder; Mary Ann Quinn-Allen; William H Kane; Barry R Lentz
Journal:  Biochemistry       Date:  2005-01-18       Impact factor: 3.162

9.  Changes in membrane phospholipid distribution during platelet activation.

Authors:  E M Bevers; P Comfurius; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1983-12-07

10.  Specificity of soluble phospholipid binding sites on human factor Xa.

Authors:  Mou Banerjee; Daryl C Drummond; Arvind Srivastava; David Daleke; Barry R Lentz
Journal:  Biochemistry       Date:  2002-06-18       Impact factor: 3.162

View more
  4 in total

1.  Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.

Authors:  Hiroshi Deguchi; Yajnavalka Banerjee; Sunia Trauger; Gary Siuzdak; Ewa Kalisiak; José A Fernández; Linh Hoang; Minerva Tran; Subramanian Yegneswaran; Darlene J Elias; John H Griffin
Journal:  Blood       Date:  2015-07-14       Impact factor: 22.113

2.  Phosphatidylserine and FVa regulate FXa structure.

Authors:  Kinshuk Raj Srivasatava; Rinku Majumder; William H Kane; Mary Ann Quinn-Allen; Barry R Lentz
Journal:  Biochem J       Date:  2014-04-01       Impact factor: 3.857

3.  Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.

Authors:  Hiroshi Deguchi; Darlene J Elias; John H Griffin
Journal:  Res Pract Thromb Haemost       Date:  2017-06-20

4.  Soluble phosphatidylserine binds to two sites on human factor IXa in a Ca2+ dependent fashion to specifically regulate structure and activity.

Authors:  Rinku Majumder; Tilen Koklic; Tanusree Sengupta; Daud Cole; Rima Chattopadhyay; Subir Biswas; Dougald Monroe; Barry R Lentz
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.